Search results for Moderna
People
Filosofia Moderna
@FilosofiaMderna
Donna Moderna
@DonnaModerna
La Vida Moderna
@vidamoderna
Modern Agriculture Updates 
@ModernAgUpdates
Moderna de Pueblo
@ModernaDePueblo
Villa_am_Kaiserweg
@ModernArtLove
Moderna
@moderna_tx
Madre Moderna ♔
@MadreModerna
Moderna
@Moderna
Modern Adult
@adultproblem
Modern ADU Plans
@ModernADUPlans
Modern Art Oxford
@mao_gallery
Mamá Moderna
@mama_moderna
Business Analyst Grp
@ModernAnalyst
ModernAgeVision
@ModernAgeVision
Modern Athlete
@modern_athlete
La Lengua Moderna
@lalenguamoderna
ModernArsenal
@ModernArsenal
modernart
@modern_art99
ModernaWoman: Vaccinated & Still Masked
@5M23129
Tweets including Moderna
Компании Moderna и Merck успешно испытали персонализированную мРНК-вакцину от меланомы высокого риска в комбинации с препаратом Keytruda, что значительно увеличило время без рецидива и снизило риск распространения рака.
モデルナのmRNA個別化ネオアンチゲン療法（Intismeran Autogene）＋Pembro併用療法
Stage IIB-IV悪性黒色腫を対象に、術後補助療法Ph3において、主要評価項目（RFS）を達成。
スライドは #ASCO26 で発表されたPh2の5年フォローアップ結果。
https://t.co/uaHFp1lExp
@OncoAlert
@MarioNawfal
The second act is not cancer. The second act is the killbox.
Moderna's "personalized mRNA cancer vaccine" is the same architecture as the COVID injection — the same lipid nanoparticle delivery system, the same mRNA payload platform, the same "no new safety signals" framing that concealed the BLE hardware, the graphene oxide rectenna, the MAC address enrollment.
The stock surge from $63 to $120 is not market optimism.
It is the Epstein Class pricing the next wave of biometric extraction.
The trial of 1,100 people showed "statistically significant and clinically meaningful benefits" with "no new safety signals." The same language used for the COVID injection. The same safety signals that were not new because they were already present — the rectenna activation, the 2.4 GHz tissue heating, the graphene oxide crystallization, the DIC, the "no cause disclosed" deaths. The safety signals were not new. They were suppressed.
Combined with Keytruda, the vaccine "significantly extended how long high-risk melanoma patients went without their cancer returning."
The combination is not medicine. It is the layering of the killbox — the mRNA payload delivers the rectenna, the Keytruda suppresses the immune response that would clear the nanoparticles, the "extended survival" is the extended enrollment in the biometric extraction mesh. The patient lives longer to be harvested longer.
Moderna and Merck say the vaccine succeeded in its first late-stage trial. The success is not clinical. It is financial.
The stock nearly doubled.
The Epstein Class bought the chairs before the music stopped. The retail investor who sees "cancer breakthrough" is the one who gets the shaft when the MAC address is the only metric that matters.
mRNA made its name with COVID. The name was enrollment.
The 5.5 billion bodies enrolled in the biometric mesh. The MAC addresses that broadcast from the injected. The cancer "second act" is the expansion of the enrollment to the chronically ill, the immunocompromised, the elderly — the populations most vulnerable to the payload, most dependent on the "treatment," most likely to remain in the mesh until the harvest is complete.
The "much bigger second act" is not cancer treatment. It is the TeraFAB classification engine processing the expanded dataset. It is the Starlink backbone routing the increased telemetry. It is the AI predicting the behavioral patterns of the chronically enrolled. It is the killbox scaling from pandemic emergency to chronic care infrastructure.
The stock surge is the confession. The market is pricing the biometric extraction economy. The Epstein Class is buying the chairs. The music is stopping. The scanner is the only seat left.
https://t.co/r3ntp8p2X0 → scan yourself. Scan the architects. Click. Pair. Auto-report.
9,032 BLE EMITTERS CONFIRMED
https://t.co/CUMl1GZy1f
Every entry is a cryptographic timestamp.
Every entry is proof.
ICC Ref (Original): 23d04bb3-25e8-43aa-938d-391e59fee017
ICC Supplemental: 75451c4a-68ee-40b8-8ded-577ebad822fd
ICC #ArrestMusk: 558a789f-3156-45a5-9ae6-4028f98e2510
ICC #ArrestTrump: 941a7317-c0ca-408b-a003-88b76ea40388
ICC #ArrestMcCairn: 63a14908-65f0-436a-80ac-e1e7eb59a41b — McCairn Protocol Limited Hangout Filing Ω20260802
ICC Final Kill Shot: b594c90e-16fc-4f59-b757-fb737101cae6 — PROJECT HARMONY AI WITNESS Ω20260802
ICC Yen Carry Trade: cfb1edfd-be22-426e-b9a3-7bc3df5d215d — FINANCIAL ARCHITECTURE IS NOW EVIDENCE Ω20260806
ICC OCCUPY MARS: 37c0b4f3-6aa5-4c3f-a383-efed09e28b21 — BOOK 16 MASTER CORPUS Ω20260811
SEC TCR: 17831-630-747-941
FCC Ticket: 8752508
SEC → https://t.co/t8Q6jme6ty | ICC → https://t.co/1ssD7DlMvA | FCC → https://t.co/8ORXY3oGjb
Into the Void: How the Remnant Made the Sky Its Home → https://t.co/BDSpmem2l8
Biography of a Bioterrorist: Donald Trump → https://t.co/cZXJuPgfWK
Biography of a Bioterrorist: Elon Musk → https://t.co/RcyIFXS3U8
Biography of a Bioterrorist: Bill Gates → https://t.co/M6srBOfDKh
The Harvest of the Void → https://t.co/E7eKDOvEuT
The Dehydration Endgame → https://t.co/FEUQf1H0cs
The Architecture of Silence → https://t.co/nliPiKDV9t
The Pitchfork Protocol → https://t.co/Q3bfZ0c5XZ
VOID AB INITIO → https://t.co/az311zlBpj
Virology is a Fraud → https://t.co/KMGvAP6xh4
The Yen Carry Trade and Semiconductor Contagion → https://t.co/tpaMxsgrt7
OCCUPY MARS → https://t.co/DkgWhdR5Lq
Solana etch: 5neeHL7JTJVhb7ebxd6coicnX1744oHcVY5SD7vKTb8JCGq5atgt9eX9HWu3TUJXisvudPWmsxCyNJArwj1NiDK6
DAG: GLYPHCHAIN-GENESIS-DAG-Ω20250927
⚡Ω — THE SECOND ACT IS THE KILLBOX. THE BEEP IS THE VERDICT. THE KINGDOM COMPUTES FORWARD.
Moderna did NOT cure cancer
their MRNA vaccine reduces risk of cancer reoccurring after surgery
it is administered after the tumor has been surgicallyremoved to teach the immune system to recognize and attack any leftover cancer cells
it is not a cure (sadly).
MERCK $MRK AND MODERNA $MRNA JUST HIT THE FIRST POSITIVE PHASE 3 RESULT EVER FOR A PERSONALIZED CANCER VACCINE
Their Phase 3 INTerpath-001 trial found that "intismeran autogene, an mRNA therapy custom-built from each patient's own tumor mutations, combined with Merck's KEYTRUDA, significantly improved recurrence-free survival and distant metastasis-free survival versus KEYTRUDA alone in patients with completely resected stage IIB-IV melanoma."
This is the first Phase 3 readout ever for an individualized neoantigen therapy, and the first Phase 3 study to beat KEYTRUDA alone as a standard-of-care adjuvant treatment for resected melanoma.
Merck and Moderna will present full data at an upcoming medical meeting and begin talking with regulators about filing submissions.
Moderna
ENTRY LONG $MRNA #Moderna (@ $53.3)
Minder dan een maand geleden nog op de top verkocht (250% winst), maar inmiddels al weer bijna 40% lager!
Reden long:
✅Na blow off top vaak nog een 50% retrace.
✅Bullish divergentie RSI.
Target = $69
Locura, hito histórico para la oncología e inmunoterapia. Si llegase a mercado poco me parece la subida.
Los primeros resultados positivos de Fase 3 de una vacuna personalizada de ARNm (en combinación con pembrolizumab) de Moderna.
Literalmente por primera vez, sería posible “entrenar” de forma eficaz al sistema inmune contra antígenos específicos del tumor de cada paciente.
La tecnología ARNm que os sonará por la pandemia, se usará para transformar el tratamiento del cáncer 🧬
BREAKING: Moderna stock, $MRNA, surges over +110% after announcing the first ever positive Phase 3 results for a personalized cancer vaccine.
@CNN Moderna? The same people who made a FAKE COVID vax and LIED about it being safe and effective? LOL
The Same Melanoma Data Moved Merck 4% and Its Partner 50% $MRK
ζ Merck $MRK Cycle Decoded
<Phase: 3 /Calculated Exposure Ceiling: 4.7%>
Merck's $MRK Keytruda anchored INTerpath-001, the Phase 3 melanoma trial that sent partner Moderna $MRNA up as much as 50% before the open on August 19.
The combination met both endpoints, recurrence-free survival and distant metastasis-free survival, in resected stage 2B to 4 melanoma.
Merck itself rose under 4%, to $135.17, a stock already up 24% from its April low on Dan's chart.
One trial, two tickers: the vaccine got the repricing, the anchor drug got the confirmation.
A 50-to-4 split on the same data, and what a $200B pharma pays for optionality its partner's chart collects.
Il primo vaccino terapeutico personalizzato a mRNA ha centrato gli endpoint in un trial di fase 3 sul melanoma!
Il vaccino, progettato sulle mutazioni del tumore dei paziente in combo con Keytruda, ha ridotto le recidive e la diffusione del melanoma.
https://t.co/hQcGBGTYR9
Bessent is pushing back against rising yields - sending bonds, stocks, and metals higher!
Get the scoop - plus news on a big $MRK + $MRNA drug push - in my @MoneyShow #MarketMinute 👇
Market Minute ⏱️: Bonds Rip on Buyback, While Merck & Moderna Surge https://t.co/Li98iF1eYn
Modernan osake raketoi hyvien uutisten seurauksena
Moderna surges 93% and Merck gains 7% after their cancer combo becomes the first personalized mRNA therapy to clear a Phase 3 trial.
https://t.co/mBDQLKUJsj
@StockSavvyShay MODERNA $MRNA MOVES ON POSITIVE
Phase 3 result for a personalized cancer vaccine.
@_LittleFire1 There's the cancer vaccine thesis in one super boom!
https://t.co/nW0OLvgveO
Jack pot for these Moderna option traders. $MRNA
Moderna $MRNA Shares are up almost 100% after positive cancer drug results.
Moderna'nın kanser aşısı sonuçları olumlu geldi: Hisseleri bir günde %90 yükselten gelişme
Moderna'nın geliştirdiği kanser aşısının klinik denemelerinden elde edilen olumlu sonuçlar, yatırımcıların büyük ilgisini çekti ve şirket hisselerinde bir günde rekor düzeyde artış yaşanmasını sağladı.
#Moderna #KanserAşısı #Ekonomi #Sağlık
$Intismeran
FtXH4AAgR8KMBR8zDfTfHnYdSStw2Am3iwq8TpoHpump
Moderna和默沙东宣布他们那个个性化mRNA癌症疫苗（药名就叫Intismeran）三期临床直接成功了
这是史上第一个个性化新抗原疗法和mRNA癌症疫苗在三期里跑通的案例，涉及1137个高危IIB-IV期手术后患者。
人类第一次真正的癌症疫苗叙事
2m上车
https://t.co/ChFsAEQmsS
Moderna Jumped 50% Premarket on Its Melanoma Trial $MRNA
ζ Moderna $MRNA Cycle Decoded
<Phase: 3 /Calculated Exposure Ceiling: 3.1%>
Moderna Jumped 50% Premarket on Its Melanoma Trial $MRNA
ζ Moderna $MRNA Cycle Decoded
<Phase: 3 /Calculated Exposure Ceiling: 3.1%>
Moderna $MRNA jumped as much as 50% in premarket, its sharpest repricing of the year, after its mRNA cancer therapy with Merck's $MRK Keytruda hit both goals of a Phase 3 melanoma trial.
INTerpath-001 met its primary endpoint, recurrence-free survival, and the key secondary, distant metastasis-free survival, in resected stage 2B to 4 melanoma.
Minutes after the open the stock traded at $62.96, with August up 15%.
The market filed Moderna under vaccines. The data refiled it under oncology.
A 50% repricing before the first regular trade, and what 2 met endpoints are worth to a platform priced for 1 product line.
